What new drugs can nephrologists look forward to in the next year or two?
Harman
Chloë
C
D000577:Amides / Q000627:therapeutic use; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use; D004334:Drug Administration Schedule; D017277:Drug Approval; D004338:Drug Combinations; D016503:Drug Delivery Systems; D004921:Erythropoietin / Q000627:therapeutic use; D052203:Ferrosoferric Oxide / Q000627:therapeutic use; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy; D053758:Nanoparticles; D009398:Nephrology; D006435:Renal Dialysis; D016559:Tacrolimus / Q000008:administration & dosage; D000077602:Tolvaptan; D000092502:Renin Inhibitors
D000577:Amides; D000959:Antihypertensive Agents; D001552:Benzazepines; D004338:Drug Combinations; D004921:Erythropoietin; D052203:Ferrosoferric Oxide; D005650:Fumarates; D007166:Immunosuppressive Agents; D016559:Tacrolimus; D000077602:Tolvaptan; D000092502:Renin Inhibitors; C446481:aliskiren